<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03034512</url>
  </required_header>
  <id_info>
    <org_study_id>AAAM9859</org_study_id>
    <secondary_id>2U54NS078059-04</secondary_id>
    <secondary_id>5U54NS078059-02</secondary_id>
    <nct_id>NCT03034512</nct_id>
  </id_info>
  <brief_title>Alpers Huttenlocher Natural History Study</brief_title>
  <acronym>Alpers</acronym>
  <official_title>Natural History Study of Alpers Huttenlocher Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a natural history study of Alpers Huttenlocher Syndrome. Patients will be followed
      over time to assess clinical symptoms for the purpose of expanding knowledge of this disorder
      in the medical community.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study team will conduct outpatient visits to the medical center on a 6 month basis, or as
      patients are able. The patients or their caregivers will complete medical and symptom
      questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>onset age</measure>
    <time_frame>2 years</time_frame>
    <description>age at onset of first symptom versus POLG mutation type</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Alpers Huttenlocher Syndrome</condition>
  <arm_group>
    <arm_group_label>Patients with Alpers-Huttenlocher</arm_group_label>
    <description>Patients confirmed to have Alpers Huttenlocher Syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Siblings</arm_group_label>
    <description>Siblings of patients with Alpers Huttenlocher Syndrome</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with Alpers Huttenlocher Syndrome (AHS) and their siblings
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All individuals of any age with confirmed Alpers Huttenlocher Syndrome (AHS) or
             siblings of confirmed AHS patients are eligible to participate. AHS requires the
             presence of polymerase gamma 1 (POLG) pathological mutations, either homozygous or
             compound heterozygote mutations, and the presence of epilepsy and either,
             developmental regression or hepatopathy. If POLG mutations are not demonstrated, AHS
             requires the presence of refractory seizures, developmental regression, and
             hepatopathy as well as two or more other clinical and laboratory findings including
             elevated cerebrospinal fluid (CSF) protein, neuroimaging showing lactate peaks,
             reduced N-acetyl aspartate with hyperintensities on T2/FLAIR in the thalamus and
             posterior head regions, optic atrophy/cortical blindness, quantitative mtDNA reduction
             (&gt;30% ) in muscle and/or liver, non-specific electron transport chain (ETC) enzyme
             deficiencies.

          -  All patients must agree to participate in the North American Mitochondrial Disease
             Consortium (NAMDC) Clinical Registry

        Exclusion Criteria:

          -  Patient does not have confirmed AHS and is not the sibling of a patient with confirmed
             AHS

          -  Not willing to participate in the NAMDC clinical Registry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michio Hirano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Russell Saneto, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Seattle Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristin Engelstad, MS</last_name>
    <phone>6467079112</phone>
    <email>ke4@cumc.columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jassim Uddin, BS</last_name>
    <phone>1212342-0267</phone>
    <email>ju2189@cumc.columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Engelstad, MS</last_name>
      <phone>212-305-6834</phone>
      <email>ke4@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jassim Uddin, BS</last_name>
      <phone>12123420267</phone>
      <email>ju2189@cumc.columbia.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Seattle Childrens Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Russel Saneto, MD</last_name>
      <phone>206-987-2100</phone>
      <phone_ext>4017</phone_ext>
      <email>russ.saneto@seattlechildrens.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rarediseasesnetwork.org/cms/namdc/Get-Involved/Studies/7405</url>
    <description>North American Mitochondrial Disease Consortium (NAMDC) Study Site</description>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2017</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2017</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Michio Hirano</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diffuse Cerebral Sclerosis of Schilder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>This study is a sub project under the North American Mitochondrial Disease Consortium. The de-identified data can be shared if investigators have Institutional Review Board (IRB) approval for a project that might include data from this study and if the NAMDC administration approves of the project</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

